..A MAJOR agreement need major time...or he's taking time...
...At least 6 month that kinnon speaks about this deal.....Good or bad sign?...
It's all about this...from CC...
In parallel, we are also pursuing our key initiative to establish a variety of strategic partnering and licensing relationships with sequencing platform on all the other companies worldwide. These types of deals take considerable time to complete. But the initial feedback from our outreach efforts has being very encouraging and we remain confident that we will have at least one major agreement in place this year, with the potential to generate the first material revenues for the company from ICE COLD-PCR. And we will keep you everyone posted on our progress towards this.
Very negative trend continue despite some good news...At least another negative quarter seems to be
discounted in the stock price...No ice cold effect possible in the second q...
...Illumina Ceo indicate recently that the way could be a combination of different tests...A partner for Tbio soon,like announced by Mr.Kinnon in the last CC?...
Aug 20 TBIO presentation Katherine Richardson, Ph.D., Vice President, Research & Development, Transgenomic, Inc.
The use of “liquid biopsies”, where limited or no tumor tissue is available, is increasingly important for molecular demographics, diagnostics and pharmacodynamic monitoring of patients during therapy. The combination of MX-ICP with many different downstream analysis platforms means that efficient detection of alterations at ≤0.01% in samples is feasible for most laboratories. Increased sensitivity using less DNA enables monitoring and detection of alterations in the low volumes of liquid biopsies for patient treatment, monitoring and surveillance.
From the PR
"“An entire day at this conference is dedicated to liquid biopsy, which is indicative of the level of interest it is generating among researchers, clinicians and the biopharma industry.”
Liquid biopsy is a future standard of care...Nothing about mutation detecton from Fmi new trial...
Foundation Medicine, Inc. (FMI) today announced the initiation of a large-scale, multi-center prospective clinical study to validate its circulating tumor DNA (ctDNA) assay for multiple, solid and hematologic tumor types. Expected to launch commercially in 2016, the ctDNA assay will complement FoundationOne® for solid tumors and FoundationOne® Heme for hematologic malignancies and provide healthcare practitioners with a full suite of analytically validated genomic profiling products to support the application of precision medicine and targeted therapies in cancer care.
“Tumor tissue obtained by biopsy is the gold standard material from which we generate the requisite molecular information to guide the optimally targeted treatment of patients with cancer,” said Francis Giles, M.D., Deputy Director of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. “Blood based ‘liquid biopsy’ assays offer the potential to define actionable molecular lesions in patients in whom a tissue specimen can’t be safely obtained or is otherwise unavailable. We’re delighted to be part of this rigorously designed study which we anticipate will help bring a new, less invasive diagnostic option to our patients with cancer.”
Crede Capital group..
Crede (Latin): To believe with strong conviction based on careful thought and analysis.
Direct Equity Investment in Public Companies
No discounts in direct equity investments.
Single investor: no "rush to the exits," portfolio companies out perform.
Crede Capital Group is not a hedge fund guided by short term performance captive capital source.
Deal terms provide lowest cost of capital for issuers.
No shorting or hedging employed.
$5 Million to $50 Million range of investments.
NO new offer,read the entire filing ...We have prepared this prospectus to allow the Selling Stockholders or their successors, assignees or other permitted transferees to sell or otherwise dispose of, from time to time, up to 3,318,048 shares of our Common Stock. The 3,318,048 shares include the following: (i) 1,473,512 shares of our Common Stock issued pursuant to the Securities Purchase Agreement, dated June 30, 2015, by and among the Company and the Selling Stockholders, or the Securities Purchase Agreement; (ii) 1,177,372 shares of Common Stock issuable upon exercise of the Series A Warrants issued pursuant to the Securities Purchase Agreement; and (iii) 667,164 shares of Common Stock issuable upon exercise of the Series B Warrants issued pursuant to the Securities Purchase Agreement. These Securities were issued in reliance on the exemption from securities registration in Section 4(2) under the Securities Act of 1933, as amended, or the Securities Act, and Rule 506 promulgated thereunder. The exercisability of each of the Series A Warrants and the Series B Warrants is subject to the Warrant Blocker. The Warrant Blocker will automatically expire 61 calendar days prior to the expiration date of the applicable Warrant. The Series A Warrants will not become exercisable until January 7, 2016, and, therefore, the 1,177,372 shares of Common Stock issuable upon exercise of the Series A Warrants will not be offered for sale by the Selling Stockholders until such Series A Warrants are exercisable and exercised by the holders thereof. The Series B Warrants have an exercise price of $0.01 per share of Common Stock and became exercisable upon issuance, except to the extent such exercise is restricted by the Warrant Blocker, and will remain exercisable through January 7, 2021.
From Illumina CC..."Different tests complementary"..
Jay T. Flatley - Chief Executive Officer & Director
Oh, sure. I mean the question on liquid biopsy is what is the right assay method or combination of assay methods that we know.
Derik De Bruin - Bank of America Merrill Lynch
Jay T. Flatley - Chief Executive Officer & Director
Aneuploidy will pick up some types of cancers. Nobody quite knows yet the fundamentals of the biology, so we don't know exactly which ones would be picked up by that method versus permutations versus fusions versus methylation. So there's many things we're exploring there, and I think lots of companies are working on this to determine what the best methods might be. And I suspect the market is going to wind up as a whole host of different tests that will be complementary to each other..
Using custom-made and commercial gene panels containing 8, 50, 190, or 16 000 amplicons, we demonstrate that fast-TT-COLD-PCR enriches mutations on all examined targets simultaneously. Incorporation of deoxyinosine triphosphate (dITP)/2,6-diaminopurine triphosphate (dDTP) in place of deoxyguanosine triphosphate (dGTP)/deoxyadenosine triphosphate (dATP) enables enrichment of Tm-increasing mutations. Serial dilution experiments demonstrate a limit of detection of approximately 0.01%-0.1% mutation abundance by use of Ion-Torrent and 0.1%-0.3% by use of Sanger sequencing.
Fast-TT-COLD-PCR improves the limit of detection of cancer gene panels by enabling mutation enrichment in multiplex, single-tube reactions. This novel adaptation of COLD-PCR converts subclonal mutations to clonal, thereby facilitating detection and subsequent mutation sequencing.
Mutation detection will give to liquid biopsy the center of the stage of diagnostic....This company can give something in this field....The big potential partners have no sufficient mutation detection in their machines...
Mutation detection...The key for the future of liquid biopsy...
Bio Rad or Rain Dance...Or illumina...They need to increase mutation sensitivity,still too high to work in
diagnostic field...This will be the news that could change the story...
Daytraders win another time today...The good news relased recently not enough to reverse long term decline...This news will be the first partnership....Mr kinnon talked about a big one this quarter...Very difficult to know who will be...Qiagen could improve 200 fold the sensitivity even of the recent PyroMark Q24 Advanced...From 2% to 0,01%...
"Combined with Pyrosequencing(®), which is a very quantitative high-resolution sequencing technology, E-ice-COLD-PCR can detect and identify mutations with a limit of detection down to 0.01 %"
Transgenomic, Inc. (TBIO), a global biotechnology company advancing precision medicine through advanced diagnostic tests and clinical and research services, today announced the launch of the Transgenomic Leukodystrophy NGS Panel for the diagnosis of leukodystrophy, a group of rare progressive genetic disorders that affect the central nervous system by disrupting the growth or maintenance of the myelin sheath insulating nerve cells.
Leukodystrophies have typically been difficult to diagnose, with definitive diagnoses taking years of testing. Previously, brain MRI scans were commonly used, but often provided non-specific results. With the advent of improved genetic testing methods, the Global Leukodystrophy Initiative (GLIA) Consortium has issued diagnostic guidelines that recommend use of a broad spectrum next-generation sequencing (NGS) panel, whole exome sequencing, or whole genome sequencing as the preferred first-line diagnostic tool. The new Transgenomic Leukodystrophy NGS Panel includes 137 genes and incorporates all of the genes GLIA recommends for testing. As the most comprehensive test on the market, it can potentially make definitive diagnoses accessible to patients and their families much earlier in the disease process.